Table 1 Baseline characteristics (n = 64)
Characteristic | DE + rh-endostatin (n = 33) n (%) | DE (n = 31) n (%) |
|---|---|---|
Age, years | ||
Median (range) | 51.5 (33–68) | 51.3 (35–67) |
Menopausal status | ||
Premenopausal | 14 (42.4) | 13 (41.9) |
Postmenopausal | 18 (54.5) | 14 (45.2) |
Perimenopausal | 1 (3.0) | 4 (12.9) |
ER status | ||
Positive | 19 (57.6) | 15 (48.4) |
Negative | 12 (36.4) | 14 (45.2) |
Unknown | 2 (6.1) | 2 (6.5) |
PR status | ||
Positive | 15 (45.5) | 14 (45.2) |
Negative | 16 (48.5) | 15 (48.4) |
Unknown | 2 (6.1) | 2 (6.5) |
HER2 status | ||
Positive | 6 (18.2) | 7 (22.6) |
Negative | 24 (72.7) | 20 (64.5) |
Unknown | 3 (9.1) | 4 (12.9) |
ECOG performance status | ||
0 | 18 (54.5) | 21 (67.7) |
1 | 12 (36.4) | 8 (25.8) |
2 | 3 (9.1) | 2 (6.5) |
Histology | ||
Ductal | 29 (87.9) | 27 (80.6) |
Lobular | 2 (6.1) | 3 (9.7) |
Others | 2 (6.1) | 1 (3.2) |
No. of metastatic lymph nodes | ||
0 | 16 (48.5) | 12 (38.7) |
1-3 | 6 (18.2) | 11 (35.5) |
4-9 | 7 (21.2) | 5 (16.1) |
≥10 | 4 (12.1) | 3 (9.7) |
TNM stage | ||
II | 22 (66.7) | 19 (61.3) |
III | 11 (33.3) | 12 (38.7) |